Company / SG&A per Share
BridgeBio Pharma, Inc. SG&A per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$2.80
FY2025
5-year range
$0.77 / $2.80
FY2021-FY2025
Trend
+69.4%
vs FY2024
Sector context
#66 of 210
Health Care
What the data says
At $2.80, BridgeBio Pharma, Inc.'s sg&a per share ranks #145 of 210 in the Health Care sector. SG&A per Share has increased for 4 consecutive years, from $0.77 in FY2021 to $2.80 in FY2025.
Based on SEC 10-K filings.
2.80 in FY2025 with a 5-year CAGR of +18.9%.
Increased from $1.28 to $2.80 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +42.2%
- 5-Year CAGR
- +18.9%
- 10-Year CAGR
- -
Sector benchmark
#145 of 210 in Health CareTop 69% of 210This company $2.80 Sector average $29.50
▼
-90.5% below sector average
Key checks
Key Insights
- BridgeBio Pharma, Inc.'s sg&a per share has grown for 4 consecutive years.
- In FY2025, sg&a per share increased 69.4% year-over-year.
- Ranks #66 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.80 | +69.4% |
| FY2024 | $1.65 | +29.3% |
| FY2023 | $1.28 | +31.3% |
| FY2022 | $0.97 | +26.5% |
| FY2021 | $0.77 | -34.8% |
| FY2020 | $1.18 | +14.9% |
| FY2019 | $1.02 | +45.2% |
| FY2018 | $0.71 | +62.3% |
| FY2017 | $0.43 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026